GPCR
Price
$17.36Alerts
Change
-$0.81 (-4.46%)
Updated
Nov 18 closing price
Capitalization
1.45B
Intraday BUY SELL Signals
IBIO
Price
$0.85Alerts
Change
+$0.10 (+13.33%)
Updated
Nov 18 closing price
Capitalization
47.5M
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GPCR vs IBIO

GPCR vs IBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GPCR vs. IBIO commentary
Nov 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GPCR is a Hold and IBIO is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GPCR with price predictions
Nov 18, 2026

GPCR's Stochastic Oscillator remains in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for GPCR just turned positive on October 20, 2026. Looking at past instances where GPCR's MACD turned positive, the stock continued to rise in 33 of 37 cases over the following month. The odds of a continued upward trend are 89%.

Following a +6.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where GPCR advanced for three days, in 177 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

GPCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GPCR as a result. In 49 of 60 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GPCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for GPCR entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.071) is normal, around the industry mean (3.592). P/E Ratio (-6.716) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. GPCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GPCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for IBIO with price predictions
Nov 18, 2026

IBIO sees its Stochastic Oscillator ascends from oversold territory

On November 18, 2026, the Stochastic Oscillator for IBIO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In 56 of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBIO's RSI Oscillator exited the oversold zone, 34 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on IBIO as a result. In 68 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for IBIO just turned positive on October 27, 2026. Looking at past instances where IBIO's MACD turned positive, the stock continued to rise in 32 of 39 cases over the following month. The odds of a continued upward trend are 82%.

Following a +20.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in 186 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for IBIO entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.554) is normal, around the industry mean (3.592). P/E Ratio (-2.308) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. IBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IBIO: Fundamental Ratings
IBIO
OUTLOOK RATING
1..100
31
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
80
P/E GROWTH RATING
1..100
11
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GPCRIBIO
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 19, 2026
Stock price -- (GPCR: $18.17 vs. IBIO: $0.75)
Brand notoriety: GPCR and IBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GPCR: 47% vs. IBIO: 57%
Market capitalization -- GPCR: $1.45B vs. IBIO: $47.5M
GPCR [@Biotechnology] is valued at $1.45B. IBIO’s [@Biotechnology] market capitalization is $47.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GPCR’s FA Score shows that 2 FA rating(s) are green while IBIO’s FA Score has 1 green FA rating(s).

  • GPCR’s FA Score: 2 green, 3 red.
  • IBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, GPCR is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GPCR’s TA Score shows that 5 TA indicator(s) are bullish while IBIO’s TA Score has 5 bullish TA indicator(s).

  • GPCR’s TA Score: 5 bullish, 3 bearish.
  • IBIO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both GPCR and IBIO are a good buy in the short-term.

Price Growth

GPCR (@Biotechnology) experienced а -16.38% price change this week, while IBIO (@Biotechnology) price change was -4.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.10%. For the same industry, the average monthly price growth was -10.38%, and the average quarterly price growth was -24.10%.

Reported Earning Dates

IBIO is expected to report earnings on Feb 16, 2027.

Industries' Descriptions

@Biotechnology (-11.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

GPCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, GPCR has been loosely correlated with WVE. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if GPCR jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GPCR
1D Price
Change %
GPCR100%
-4.46%
WVE - GPCR
65%
Loosely correlated
-2.46%
KYMR - GPCR
63%
Loosely correlated
-0.32%
OCUL - GPCR
43%
Loosely correlated
-1.33%
FULC - GPCR
41%
Loosely correlated
-0.80%
OLMA - GPCR
39%
Loosely correlated
-2.22%
More

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with WVE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
+13.37%
WVE - IBIO
47%
Loosely correlated
-2.46%
GPCR - IBIO
39%
Loosely correlated
-4.46%
REPL - IBIO
38%
Loosely correlated
+0.61%
KYMR - IBIO
37%
Loosely correlated
-0.32%
AVTX - IBIO
36%
Loosely correlated
-6.03%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KAUG27.870.08
+0.28%
Innovator US Small Cap Power Buffer ETF - August (KAUG)
JANW39.13N/A
+0.01%
AllianzIM U.S. Equity Buffer20 Jan ETF (JANW)
GJS23.49N/A
N/A
Synthetic Fixed-Income Securities STRATS 2006-2 Goldman Sachs Group
BKWO37.72N/A
N/A
BNY Mellon Womens's Opportunities ETF
PAUG45.71-0.05
-0.11%
Innovator U.S. Equity Power Buffer ETF - August (PAUG)